Artwork

BioTechniques에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BioTechniques 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

The ethics of whole-genome sequencing: from race and religion to science fiction

27:17
 
공유
 

Manage episode 295913909 series 2902208
BioTechniques에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BioTechniques 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Welcome to part two of this two-part episode on whole-genome sequencing (WGS) in rare disease research and treatment. In part one we discussed the impacts the technology has had on both improving the clinical diagnosis and management of rare diseases and on drug development and basic research studies.


This episode goes beyond the technology’s capabilities and into the debates surrounding how, when and why they should be used. What needs to change for the technique to be applied equitably? And how does reality stack up against science fiction in terms of people’s perceptions of ubiquitous WGS?


To do this I speak with David Dimmock, Senior Medical Director of the Rady Children’s Institute for Genomic Medicine (CA, USA); Christine Stanley, Chief Director of Clinical Genomics, Variantyx (MA, USA); and Take Ogawa, Vice President of Sales & Marketing at Psomagen (MD, USA). Each of these speakers provides their opinions on the impacts of race, religion and way of life on the application of WGS and how much is too much data.


Contents:

  • Introductions: 00:00-02:20
  • Gauging public perceptions of routine WGS 02:20-05:40
  • The role of industry in improving WGS accessibility and capabilities: 05:40-07:35
  • The appropriate use of pre-symptomatic and predictive risk findings: 08:00-11:15
  • Debating the discovery of untreatable diseases: 11:15-12:45
  • The impact of data biases in gene sequencing and the lack of gene references for different populations: 12:45-14:45
  • The impact of religion and lifestyle on ethical considerations in the use of WGS data: 14:45-16:00
  • Dealing with unintended findings or results that impact relatives: 16:00-16:45
  • The value of WGS in pharmacogenomic variant findings and challenging the ACMG59 list: 16:45-19:20
  • Striking the balance between fully utilizing WGS for all potential findings and ensuring maximum participation for all groups: 19:20-22:45
  • Filtering data to avoid exclusion: 22:45-24:10
  • Who owns WGS data? 24:10-25:15
  • Consent conversations: 25:15-26:30
  • Final comments: 26:30-27:15


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

57 에피소드

Artwork
icon공유
 
Manage episode 295913909 series 2902208
BioTechniques에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BioTechniques 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Welcome to part two of this two-part episode on whole-genome sequencing (WGS) in rare disease research and treatment. In part one we discussed the impacts the technology has had on both improving the clinical diagnosis and management of rare diseases and on drug development and basic research studies.


This episode goes beyond the technology’s capabilities and into the debates surrounding how, when and why they should be used. What needs to change for the technique to be applied equitably? And how does reality stack up against science fiction in terms of people’s perceptions of ubiquitous WGS?


To do this I speak with David Dimmock, Senior Medical Director of the Rady Children’s Institute for Genomic Medicine (CA, USA); Christine Stanley, Chief Director of Clinical Genomics, Variantyx (MA, USA); and Take Ogawa, Vice President of Sales & Marketing at Psomagen (MD, USA). Each of these speakers provides their opinions on the impacts of race, religion and way of life on the application of WGS and how much is too much data.


Contents:

  • Introductions: 00:00-02:20
  • Gauging public perceptions of routine WGS 02:20-05:40
  • The role of industry in improving WGS accessibility and capabilities: 05:40-07:35
  • The appropriate use of pre-symptomatic and predictive risk findings: 08:00-11:15
  • Debating the discovery of untreatable diseases: 11:15-12:45
  • The impact of data biases in gene sequencing and the lack of gene references for different populations: 12:45-14:45
  • The impact of religion and lifestyle on ethical considerations in the use of WGS data: 14:45-16:00
  • Dealing with unintended findings or results that impact relatives: 16:00-16:45
  • The value of WGS in pharmacogenomic variant findings and challenging the ACMG59 list: 16:45-19:20
  • Striking the balance between fully utilizing WGS for all potential findings and ensuring maximum participation for all groups: 19:20-22:45
  • Filtering data to avoid exclusion: 22:45-24:10
  • Who owns WGS data? 24:10-25:15
  • Consent conversations: 25:15-26:30
  • Final comments: 26:30-27:15


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

57 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드